Fig. 3From: Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trialsForest plot of studies with patients switching with serious drug-related AEsBack to article page